Multiple roles of HDAC inhibition in neurodegenerative conditions

Trends in Neurosciences

Volumn 32, Issue 11, 2009, Pages 591-601

  Chuang, De Maw ^a   Leng, Yan ^a   Marinova, Zoya ^a   Kim, Hyeon Ju ^a   Chiu, Chi Tso ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AEOL 10150; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LITHIUM; NICOTINAMIDE; RILUZOLE; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUNTINGTON CHOREA; LEARNING; LOW DRUG DOSE; MEMORY; MENTAL PERFORMANCE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SPINAL MUSCULAR ATROPHY; TREATMENT DURATION;

ACETYLATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HUNTINGTON DISEASE; MUSCULAR ATROPHY, SPINAL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; STROKE;

EID: 70350018325     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2009.06.002     Document Type: Review

References (105)

1. Mai A., et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25 (2005) 261-309
2. Langley B., et al. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 41-50
3. Abel T., and Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8 (2008) 57-64
4. Kazantsev A.G., and Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7 (2008) 854-868
5. Bartsch O., et al. DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS. Hum. Genet. 117 (2005) 485-493
6. Itoh Y., et al. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 14 (2008) 529-544
7. Marks P.A., and Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert. Opin. Investig. Drugs 14 (2005) 1497-1511
8. Carey N., and La Thangue N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6 (2006) 369-375
9. Michishita E., et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16 (2005) 4623-4635
10. Voelter-Mahlknecht S., et al. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol. Med. 16 (2005) 589-598
11. Hubbert C., et al. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002) 455-458
12. Phiel C.J., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
13. Göttlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
14. Gurvich N., et al. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64 (2004) 1079-1086
15. Butler R., and Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 7 (2006) 784-796
16. Khan N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008) 581-589
17. Haggarty S.J., et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4389-4394
18. Mai A., et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48 (2005) 3344-3353
19. Trapp J., et al. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). Chem. Med. Chem. 2 (2007) 1419-1431
20. Green K.N., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 28 (2008) 11500-11510
21. Rouaux C., et al. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22 (2003) 6537-6549
22. Ryu H., et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4281-4286
23. Jeong M.R., et al. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 542 (2003) 74-78
24. Biswas S.C., et al. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J. Neurosci. 25 (2005) 8349-8358
25. Langley B., et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 28 (2008) 163-176
26. Uo T., et al. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J. Neurosci. 29 (2009) 2824-2832
27. Chuang D.-M. Lithium protection from glutamate excitotoxicity: therapeutic implications. Clin. Neurosci. Res. 4 (2004) 243-252
28. Leng Y., and Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26 (2006) 7502-7512
29. Kanai H., et al. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 4 (2004) 336-344
30. Chuang D.M., et al. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 269-290
31. Sen N., et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 10 (2008) 866-873
32. Monti B., et al. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J. Neurochem. 103 (2007) 518-530
33. Kontopoulos E., et al. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15 (2006) 3012-3023
34. Leng Y., et al. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28 (2008) 2576-2588
35. Yasuda S., et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14 (2009) 51-59
36. Chen P.S., et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006) 1116-1125
37. Wu X., et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11 (2008) 1123-1134
38. Peng G.S., et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134 (2005) 162-169
39. Chen P.S., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007) 203-212
40. Huuskonen J., et al. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J. Pharmacol. 141 (2004) 874-880
41. Ren M., et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004) 1358-1367
42. Kim H.J., et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
43. Faraco G., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70 (2006) 1876-1884
44. Kim H., et al. The histone deacetylase inhibitor, sodium butyrate, stimulates cell proliferation in the ischemic brain: roles of BDNF-TrkB signaling. J. Neurochem. 110 (2009) 1226-1240
45. Qi X., et al. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66 (2004) 899-908
46. Zheng Z., et al. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J. Cereb. Blood Flow Metab. 28 (2008) 53-63
47. Meisel A., et al. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J. Neurochem. 98 (2006) 1019-1031
48. Yildirim F., et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 210 (2008) 531-542
49. Sinn D.I., et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 26 (2007) 464-472
50. Granger A., et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22 (2008) 3549-3560
51. Hodges A., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15 (2006) 965-977
52. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003) 233-238
53. Hahnen E., et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 17 (2008) 169-184
54. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001) 739-743
55. Bates E.A., et al. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26 (2006) 2830-2838
56. Pallos J., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17 (2008) 3767-3775
57. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137 (2009) 60-72
58. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2041-2046
59. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
60. Sadri-Vakili G., et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16 (2007) 1293-1306
61. Thomas E.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 15564-15569
62. Gardian G., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280 (2005) 556-563
63. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
64. Hay D.G., et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13 (2004) 1389-1405
65. Tagawa K., et al. The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J. Neurosci. 27 (2007) 868-880
66. Dompierre J.P., et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27 (2007) 3571-3583
67. Iwata A., et al. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 280 (2005) 40282-40292
68. Pandey U.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007) 859-863
69. Ryu H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93 (2005) 1087-1098
70. Del Signore S.J., et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 10 (2009) 85-94
71. Petri S., et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22 (2006) 40-49
72. Ferraiuolo L., et al. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J. Neurosci. 27 (2007) 9201-9219
73. Sugai F., et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 20 (2004) 3179-3183
74. Rouaux C., et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27 (2007) 5535-5545
75. Feng H.L., et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155 (2008) 567-572
76. Cudkowicz M.E., et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 10 (2009) 99-106
77. Chang J.G., et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9808-9813
78. Andreassi C., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12 (2004) 59-65
79. Sumner C.J., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54 (2003) 647-654
80. Brichta L., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12 (2003) 2481-2489
81. Hahnen E., et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 98 (2006) 193-202
82. Riessland M., et al. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 120 (2006) 101-110
83. Hauke J., et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum. Mol. Genet. 18 (2009) 304-317
84. Avila A.M., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117 (2007) 659-671
85. Kernochan L.E., et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14 (2005) 1171-1182
86. Tsai L.K., et al. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol. Dis. 24 (2006) 286-295
87. Tsai L.K., et al. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J. Mol. Med. 86 (2008) 1243-1254
88. Tsai L.K., et al. Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy. Neurobiol. Dis. 31 (2008) 361-367
89. Mercuri E., et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 14 (2004) 130-135
90. Brahe C., et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13 (2005) 256-259
91. Brichta L., et al. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 59 (2006) 970-975
92. Weihl C.C., et al. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 67 (2006) 500-501
93. Tsai L.K., et al. Valproic acid treatment in six patients with spinal muscular atrophy. Eur. J. Neurol. 14 (2007) e8-9
94. Gardian G., et al. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 5 (2004) 235-241
95. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3 (2002) 383-394
96. Outeiro T.F., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007) 516-519
97. Su Y., et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43 (2004) 6899-6908
98. Fischer A., et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007) 178-182
99. Kim D., et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60 (2008) 803-817
100. Guan J.S., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009) 55-60
101. Barrett R.M., and Wood M.A. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn. Mem. 15 (2008) 460-467
102. Ricobaraza A., et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34 (2009) 1721-1732
103. Qing H., et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 205 (2008) 2781-2789
104. Kim D., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26 (2007) 3169-3179
105. Bruserud O., et al. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8 (2007) 388-400